“In the case of iLet, we're going to say, this is how much insulin they're getting for what they consider to be a usual meal. And we learn that and we can set it that way. So we just take the responsibility of learning carb counting, which is really tough, off the user's plate. That's an extra level of automation that traditional pumps don't provide,” Beta Bionics CEO Sean Saint explains to Bloomberg Intelligence. In this episode of Vanguards of Health Care, Saint sits down with BI analyst Matt Henriksson for an in-depth interview about Beta’s iLet pump, designed to eliminate the human stress of making insulin dosing decisions. The conversation also touches on the company’s pay as you go strategy through the pharmacy channel and future product development, including the Mint patch pump.
See omnystudio.com/listener for privacy information.
Vanguards of Health Care by Bloomberg Intelligence